For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
‘So they did not die in vain’: One single committee accountable for mortality reviews
+Opinion
In print
‘So they did not die in vain’: One single committee accountable for mortality reviews
Wednesday 19 July 2023, 03:06 PM

Past mortality review committees have often advocated to no avail for changes that could prevent deaths [Image: Zinko Hein on Unsplash]
On 1 July, changes recommended by a 2021 review of the national mortality review function at Te Tāhū Hauora Health Quality & Safety Commission took effect. Don Matheson explains what has changed and why
After national mortality reviews came under scrutiny, it was recommended that the five separate mortality review committees be replaced by a single Na
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References